Stockreport

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing [Yahoo! Finance]

Pfizer, Inc.  (PFE) 
Last pfizer, inc. earnings: 4/28 06:45 am Check Earnings Report
PDF VH184, the first, third-generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals Additional in-vitro data on VH184 demons [Read more]